Clinical Study of Recombinant Factor VIII (BL-160) in Hemophilia A Patients
スポンサーリンク
概要
- 論文の詳細を見る
Phase I and II clinical studies were performed to evaluate the safety, efficacy and pharmacokinetics of recombinant factor VIII (BL-160) in hemophilia A patients. Three and seven patients were enrolled in the phase I and phase II study respectively. The half life and recovery observed with recombinant factor VIII were comparable to those observed with plasma-derived factor VIII (Hemofil M). Forty-four bleeding episodes were treated with recombinant factor VIII during the phase II study, hemostatic effects were excellent in 39 and good in 5 bleeding episodes. There is no evidence of neoantigenicity resulting from potential contaminating proteins used in production steps. No adverse reactions were reported. These data indicate that recombinant factor VIII is safe and efficacious for the treatment of bleeding episodes in hemophilia A.
- 一般社団法人 日本血栓止血学会の論文
一般社団法人 日本血栓止血学会 | 論文
- 日本人のＡＤＡＭＴＳ１３
- Infection of specific strains of Streptococcus mutans exacerbated intracerebral hemorrhage
- Transcriptional regulation of megakaryopoiesis and thrombopoiesis
- 新規血小板活性化受容体ＣＬＥＣ－２ その発見から今後の展望まで:その発見から今後の展望まで
- １．臨床血栓止血学オーバービュー